For Industry

Patient-Focused Drug Development Public Meeting for Alopecia Areata

On September 11, 2017, FDA is conducting a public meeting on Alopecia Areata Patient-Focused Drug Development. FDA is interested in obtaining patient input on the impact of alopecia areata, including on daily life, patient views on treatment approaches, and decision factors taken into account when selecting a treatment.

This website will be updated as meeting materials are developed.

September 11, 2017

1pm – 5pm

FDA White Oak Campus
10903 New Hampshire Ave.
Building 31 Conference Center (Great Room)
Silver Spring, MD 20993
(Information about arrival to FDA’s White Oak campus)

Registration: Public Meeting for Patient-Focused Drug Development on Alopecia Areatadisclaimer icon


Public Docket: In addition to proving input at the public meeting, stakeholders are invited to provide their perspectives on the discussion questions through the public docket. The docket closes on November 13, 2017.

Page Last Updated: 03/28/2018
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English